[go: up one dir, main page]

HUP0300434A3 - Oxazole derivatives and their uses as tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them - Google Patents

Oxazole derivatives and their uses as tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them

Info

Publication number
HUP0300434A3
HUP0300434A3 HU0300434A HUP0300434A HUP0300434A3 HU P0300434 A3 HUP0300434 A3 HU P0300434A3 HU 0300434 A HU0300434 A HU 0300434A HU P0300434 A HUP0300434 A HU P0300434A HU P0300434 A3 HUP0300434 A3 HU P0300434A3
Authority
HU
Hungary
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
tyrosine kinase
kinase inhibitors
Prior art date
Application number
HU0300434A
Other languages
English (en)
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of HUP0300434A2 publication Critical patent/HUP0300434A2/hu
Publication of HUP0300434A3 publication Critical patent/HUP0300434A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0300434A 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them HUP0300434A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000106836 2000-04-07
PCT/JP2001/002937 WO2001077107A1 (en) 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
HUP0300434A2 HUP0300434A2 (hu) 2003-06-28
HUP0300434A3 true HUP0300434A3 (en) 2004-11-29

Family

ID=18619943

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300434A HUP0300434A3 (en) 2000-04-07 2001-04-05 Oxazole derivatives and their uses as tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them

Country Status (19)

Country Link
US (2) US6716863B2 (hu)
EP (1) EP1268473A1 (hu)
KR (1) KR20020028865A (hu)
CN (1) CN1444582A (hu)
AU (1) AU2001244726A1 (hu)
BR (1) BR0109851A (hu)
CA (1) CA2404760A1 (hu)
CO (1) CO5261589A1 (hu)
CZ (1) CZ20023264A3 (hu)
EE (1) EE200200576A (hu)
HU (1) HUP0300434A3 (hu)
IL (1) IL152115A0 (hu)
MX (1) MXPA02009621A (hu)
NO (1) NO20024742L (hu)
OA (1) OA12244A (hu)
PE (1) PE20011178A1 (hu)
PL (1) PL365787A1 (hu)
SK (1) SK14132002A3 (hu)
WO (1) WO2001077107A1 (hu)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6004999A (en) * 1998-10-08 2000-04-26 Takeda Chemical Industries Ltd. Agents for retarding change of hormone-dependent cancer into hormone-independentcancer
CA2415961A1 (en) * 2000-07-19 2002-01-24 Hirohiko Nishiyama Production method of 1-substituted-1,2,3-triazole derivatives
EP1382350A4 (en) * 2001-04-25 2006-01-04 Takeda Pharmaceutical MEANS AGAINST THE PROPHYLAXIS BEFORE POSTOPERATIVE REPEAT OF PREMOPEOPAUSAL BREAST CANCER
US20040138160A1 (en) * 2001-04-27 2004-07-15 Kenichiro Naito Preventive/therapeutic method for cancer
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
ATE498408T1 (de) * 2001-08-10 2011-03-15 Takeda Pharmaceutical Gnrh-agonistische kombinationsmittel
US6984653B2 (en) * 2001-10-05 2006-01-10 Takeda Pharmaceutical Company Limited Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof
WO2003041739A1 (fr) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Agents anticancer
EP1460067A4 (en) * 2001-11-26 2005-12-07 Takeda Pharmaceutical BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
WO2003059907A1 (en) * 2002-01-17 2003-07-24 Takeda Chemical Industries, Ltd. Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
AU2003231098A1 (en) 2002-04-25 2003-11-10 University Of Connecticut Health Center Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
NZ540664A (en) * 2002-12-16 2007-09-28 Kissei Pharmaceutical Solid drug for oral use
TW200505913A (en) * 2003-03-28 2005-02-16 Hoffmann La Roche Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
AR044098A1 (es) * 2003-04-30 2005-08-24 Hoffmann La Roche Derivados de anilina, su elaboracion, composiciones farmaceuticas y su uso para elaborar medicamentos para el tratamiento del cancer
US7247649B2 (en) * 2003-08-13 2007-07-24 Hoffmann-La Roche Inc. Oxazoles, their manufacture and use as pharmaceutical agents
US7259262B2 (en) 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents
US20050186275A1 (en) * 2004-02-23 2005-08-25 Standard Chem. & Pharm. Co. Ltd. Sustained release tamsulosin formulations
TW200612914A (en) * 2004-03-05 2006-05-01 Hoffmann La Roche Novel oxidized thioether derivatives, their manufacture and use as pharmaceutical agents
TW200531688A (en) 2004-03-05 2005-10-01 Hoffmann La Roche Novel pentafluorosulfanyl compounds, their manufacture and use as pharmaceutical agents
TW200533346A (en) * 2004-03-18 2005-10-16 Hoffmann La Roche Novel ether derivatives, their manufacture and use as pharmaceutical agents
CA2561206A1 (en) * 2004-04-02 2005-10-20 F. Hoffmann-La Roche Ag Novel diazine derivatives, their manufacture and use as pharmaceutical agents
US7163953B2 (en) * 2004-05-25 2007-01-16 Hoffmann-La Roche Inc. Benzylether derivatives
US7005526B2 (en) * 2004-05-25 2006-02-28 Hoffmann-La Roche Inc. Thioether derivatives
US7618769B2 (en) * 2004-06-07 2009-11-17 Applied Materials, Inc. Textured chamber surface
US7288557B2 (en) 2004-09-21 2007-10-30 Hoffmann-La Roche Inc. Triazole derivatives
TW200616951A (en) * 2004-09-22 2006-06-01 Hoffmann La Roche Indole derivatives, their manufacture and use as pharmaceutial agents
AR050652A1 (es) * 2004-09-24 2006-11-08 Hoffmann La Roche Derivados de oxazol, preparacion y uso como inhibidores de la tirosina quinasa
US20060116407A1 (en) * 2004-11-22 2006-06-01 Birgit Bossenmaier Amide derivatives
TW200727900A (en) * 2005-07-27 2007-08-01 Yakult Honsha Kk Aqueous solution preparation containing camptothecins
TW200738680A (en) * 2005-08-04 2007-10-16 Hoffmann La Roche Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents
EP1915370A1 (en) * 2005-08-08 2008-04-30 F.Hoffmann-La Roche Ag Pyrazole derivatives, their manufacture and their use as pharmaceutical agents
EP1934210A1 (en) * 2005-09-30 2008-06-25 F.Hoffmann-La Roche Ag Diazine azole derivatives, their manufacture and use as pharmaceutical agents
WO2008034579A1 (en) * 2006-09-20 2008-03-27 F. Hoffmann-La Roche Ag 2-heterocyclyl-5-phenoxymethylpyridine derivatives as anticancer agents
CA2673097A1 (en) 2006-12-12 2008-06-19 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2008133102A1 (ja) 2007-04-20 2008-11-06 Daido Chemical Corporation 新規乾式固体分散体用基剤、該基剤を含有する固体分散体及び該分散体を含有する組成物
TW200944528A (en) 2008-03-12 2009-11-01 Takeda Pharmaceutical Fused heterocyclic compound
WO2010036917A1 (en) * 2008-09-26 2010-04-01 Takeda Pharmaceutical Company Limited Prevention and treatment of cancer with ras gene mutation
AR073679A1 (es) * 2008-09-26 2010-11-24 Takeda Pharmaceutical Prevencion y tratamiento de cancer con la no expresion de lkb1 supresion o mutacion, composicion farmaceutica. usos
KR101442069B1 (ko) 2009-09-30 2014-09-18 가부시키가이샤 상기 난용성 물질의 수용해성 개선방법
EP2540286A4 (en) 2010-02-26 2015-05-27 Nisshin Kasei Co Ltd HARTKAPSEL AND METHOD FOR THE PRODUCTION THEREOF
US8993634B2 (en) 2010-06-02 2015-03-31 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to Her2/neu receptor complex
WO2011153050A1 (en) 2010-06-02 2011-12-08 The Trustees Of The University Of Pennsylvania Methods and use of compounds that bind to her2/neu receptor complex
JP5909796B2 (ja) 2012-03-02 2016-04-27 株式会社サンギ 難溶性物質の水溶解性改善方法
WO2014050910A1 (ja) 2012-09-26 2014-04-03 武田薬品工業株式会社 固体粒子の製造方法
US9468681B2 (en) 2013-03-01 2016-10-18 California Institute Of Technology Targeted nanoparticles
CN111643479B (zh) 2015-07-01 2023-10-27 加州理工学院 基于阳离子粘酸聚合物的递送系统
EP3238711B1 (en) 2016-04-26 2023-07-12 Mitsubishi Chemical Corporation Base for solid dispersion, production method for solid dispersion using same, and solid dispersion
CA2995617A1 (en) * 2017-11-03 2019-05-03 Universite De Montreal Heterocyclic mitochondrial activity inhibitors and uses thereof
WO2019241327A1 (en) 2018-06-13 2019-12-19 California Institute Of Technology Nanoparticles for crossing the blood brain barrier and methods of treatment using the same
KR20210107069A (ko) 2018-12-21 2021-08-31 다이이찌 산쿄 가부시키가이샤 항체-약물 컨쥬게이트와 키나아제 저해제의 조합
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
CN114217025B (zh) * 2021-12-17 2024-01-23 哈尔滨工业大学 评估空气质量浓度预测中气象数据对其影响的分析方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0525109A4 (en) * 1990-04-16 1993-06-30 Rhone-Poulenc Rorer International (Holdings) Inc. Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase
KR20000065227A (ko) * 1996-07-19 2000-11-06 다께다 구니오 복소환 화합물, 그의 제조방법 및 용도

Also Published As

Publication number Publication date
CO5261589A1 (es) 2003-03-31
EP1268473A1 (en) 2003-01-02
US6716863B2 (en) 2004-04-06
NO20024742L (no) 2002-11-25
MXPA02009621A (es) 2003-05-14
IL152115A0 (en) 2003-05-29
WO2001077107A1 (en) 2001-10-18
HUP0300434A2 (hu) 2003-06-28
KR20020028865A (ko) 2002-04-17
BR0109851A (pt) 2003-06-03
US20040024035A1 (en) 2004-02-05
SK14132002A3 (sk) 2003-04-01
CA2404760A1 (en) 2001-10-18
AU2001244726A1 (en) 2001-10-23
WO2001077107A8 (en) 2003-02-13
OA12244A (en) 2006-05-10
NO20024742D0 (no) 2002-10-02
CN1444582A (zh) 2003-09-24
EE200200576A (et) 2004-06-15
CZ20023264A3 (cs) 2003-02-12
PE20011178A1 (es) 2001-11-19
PL365787A1 (en) 2005-01-10
WO2001077107B1 (en) 2001-12-20
US20020173526A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
HUP0300434A3 (en) Oxazole derivatives and their uses as tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0204083A3 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0301117A3 (en) Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
HUP0300565A3 (en) 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors, their use, process for their preparation and pharmaceutical compositions containing them
IL153997A0 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
HUP0203453A3 (en) Quinazoline derivatives as vegf inhibitors, process for their preparation, pharmaceutical compositions containing them and their use
HUP0301688A3 (en) Amino alcohol derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0302487A3 (en) New mandelic acid derivatives and their use as throbin inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0301742A3 (en) Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
HUP0402245A3 (en) Pyrimidinyl-aminobenzamide derivatives as glycogen synthase kinase 3betha inhibitors, their use, pharmaceutical compositions containing them and process for producing them
HUP0400989A3 (en) Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0301315A3 (en) Benzothiazole derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP0400908A3 (en) Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them
HUP0204410A3 (en) Pyrimidine-4-one derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0402454A3 (en) Substituted quinazoline derivatives as inhibitors of aurora kinases, process for their preparation and pharmaceutical compositions containing them
HUP0303016A3 (en) Xanthine phosphodiesterase v inhibitors, process for their preparation and pharmaceutical compositions containing them and their use
IL156662A0 (en) Oxazolidinone derivatives, process for the preparation thereof and pharmaceutical compositions containing the same
AU2002358676A1 (en) Hydroxyphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
HUP0200816A3 (en) Substituted 3-cyano-[1.7], [1.5], and [1.8]-naphthyridine inhibitors of tyrosine kinases, process for their preparation and pharmaceutical compositions containing them
HUP0303737A3 (en) Indolinones, substituted in position 6, and their use as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
HUP0303045A3 (en) Pyrimidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0204001A3 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0303361A3 (en) Substituted 1-aminobutan-3-ol derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0303105A3 (en) Novel aminocyclohexane derivatives, process for their preparation, pharmaceutical compositions containing them and their use
HUP0202988A3 (en) Substituted 3-phenyl-5-alkoxi-1,3,4-oxdiazol-2-one derivatives and their use as lipase inhibitors, process for their preparation and pharmaceutical compositions containing them